STBT5:Ewing sarcoma: Difference between revisions - Compendium of Cancer Genome Aberrations

(2 intermediate revisions by the same user not shown)

Line 29:

|}

~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~

(''Instructions: The table will have the diagnostic criteria from the WHO book autocompleted; remove any non-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')

~~{| class="wikitable"~~

|+

|WHO Essential Criteria (Genetics)*

|

|-

|WHO Desirable Criteria (Genetics)*

|

|-

~~|Other Classification~~

|

|}

<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home WHO Classification of Tumours].

==Related Terminology==

~~(''Instructions: The table will have the related terminology from the WHO autocompleted.)''~~

{| class="wikitable"

|+

|Acceptable

|

|N/A

|-

|Not Recommended

|

|Askin tumour (for Ewing sarcoma arising in the chest wall); primitive neuroectodermal tumour

|}

Note: Some small round cell sarcomas previously considered subtypes of Ewing sarcoma (Ewing-like sarcomas) are genetically and clinically distinct entities and include CIC-rearranged sarcoma and sarcoma with BCOR genetic alterations, described in separate sections.

==Gene Rearrangements==

Line 118:

Line 106:

{| class="wikitable sortable"

|-

!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~

!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|EXAMPLE:

Line 173:

Line 161:

!Chromosomal Pattern

!Molecular Pathogenesis

!~~'''~~Prevalence -~~'''~~

!Prevalence -

~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|EXAMPLE:

Line 206:

Line 194:

{| class="wikitable sortable"

|-

!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~

!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -

~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|EXAMPLE:''EGFR''

@@ Line 29: / Line 29: @@
 |}
-==WHO Essential and Desirable Genetic Diagnostic Criteria==
-<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
-{| class="wikitable"
-|+
-|WHO Essential Criteria (Genetics)*
-|
-|-
-|WHO Desirable Criteria (Genetics)*
-|
-|-
-|Other Classification
-|
-|}
-<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
 ==Related Terminology==
-<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
 {| class="wikitable"
 |+
 |Acceptable
-|
+|N/A
 |-
 |Not Recommended
-|
+|Askin tumour (for Ewing sarcoma arising in the chest wall); primitive neuroectodermal tumour
 |}
+Note: Some small round cell sarcomas previously considered subtypes of Ewing sarcoma (Ewing-like sarcomas) are genetically and clinically distinct entities and include CIC-rearranged sarcoma and sarcoma with BCOR genetic alterations, described in separate sections.
 ==Gene Rearrangements==
@@ Line 118: / Line 106: @@
 {| class="wikitable sortable"
 |-
-!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
+!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |<span class="blue-text">EXAMPLE:</span>
@@ Line 173: / Line 161: @@
 !Chromosomal Pattern
 !Molecular Pathogenesis
-!'''Prevalence -'''
+!Prevalence -
-'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
+Common >20%, Recurrent 5-20% or Rare <5% (Disease)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |<span class="blue-text">EXAMPLE:</span>
@@ Line 206: / Line 194: @@
 {| class="wikitable sortable"
 |-
-!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
+!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
-'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
+Common >20%, Recurrent 5-20% or Rare <5% (Disease)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  '''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |<span class="blue-text">EXAMPLE:</span>''EGFR''